In re QIAGEN India Private Limited (CAAR Delhi)
The Customs Authority for Advance Rulings, Delhi examined an application seeking advance rulings on the classification and customs duty exemption eligibility of various molecular biology and diagnostic research items imported into India. The applicant had filed the application under Section 28H of the Customs Act, 1962, to obtain clarity on the correct tariff classification of several products consisting primarily of solutions of nucleotides, nucleosides, or synthetic oligonucleotides, and on their eligibility for exemption from Basic Customs Duty.
The imported items included products such as RT2qPCR Primer Assays, QuantiNova LNA PCR Assays, miRCURY LNA miRNA Inhibitors and Mimics, Carrier RNA (Poly A), and FlexiTube GeneSolution kits. As described in the application and supporting submissions, all these products shared a common characteristic: they consisted of chemically defined nucleic acid molecules or modified nucleic acids (such as siRNA, miRNA, or LNA-based oligonucleotides), supplied either in solution or dried form. These products were used in molecular biology, genomics, gene expression analysis, RNA interference studies, and research and development activities.
Initially, the applicant had classified many of these items under CTH 38229090 and paid customs duty accordingly. Upon review, the applicant contended that this classification was erroneous and sought a ruling to determine whether the goods were more appropriately classifiable under CTH 29349990, which covers “other” chemically defined organic compounds under Chapter 29 of the Customs Tariff Act, 1975. The applicant also claimed exemption from Basic Customs Duty under Entry 167(A) of Notification No. 50/2017-Customs, contending that the goods were diagnostic kits containing solutions of nucleotides or nucleosides.
